10月15日，凯莱英盘中上涨3.46%，报148.6港元，成交额1690.87万港元。
消息面上，公募首份三季报显示，南方港股医药行业混合将凯莱英升至第一大重仓股，并在季内明显加仓创新药及CXO板块，带动市场对公司配置价值的关注回升。
同时，公司董事会将于10月22日审议前三季度业绩。此前公司披露在手订单16.73亿美元，同比增长53.77%，叠加化学大分子基地通过美国FDA批准前检查，基本面预期对股价形成支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.